Does BIORESTORATIVE THERAPIES, INC. have an economic moat?

Based on its FY2025 SEC filings, the Moat Index scores BIORESTORATIVE THERAPIES, INC. (BRTX) 49.5 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 99, returns on capital 0, balance-sheet safety 55, capital discipline 44.

How has BRTX's Moat Score changed over time?

The record logs 4 readings since Jul 17, 2026; the latest reads 49.5 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

The Moat Index

BIORESTORATIVE THERAPIES, INC.

BRTX · Healthcare · $3.0M mkt cap · FY2025 filings · Shallow moat ·

Doesn't clear the bar

Shallow moat

The four filters

Pricing power99

Median gross margin 99.7% over 5y, very stable.

Returns on capital0

Median ROIC -131.8%, above the 9% hurdle in 0% of years.

Balance-sheet safety55

Net cash position — no leverage risk.

Capital discipline44

Owner earnings trend unclear, share count n/a.

Margin of safety

Above valueOn sale

No price data

Owner earnings (normalized): —
Est. intrinsic value / share: —
Recent price: $0.33
Discount to value: No price data

Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

18 years of fundamentals

The business, in plain English

BIORESTORATIVE THERAPIES, INC. booked $359700 of revenue in FY2025 in the Healthcare sector and kept 93.4% of it as gross profit — a high-margin business by that measure. After every other cost, −3959.4% of each revenue dollar reached the bottom line.

It earned −114.3% on invested capital in FY2024, with a median of −131.8% across 3 filed years. The Returns on Capital filter above scores it 0/100.

The balance sheet carried $250000 of total debt in FY2021. Balance-Sheet Safety scores it 55/100.

The share count fell 98.0% between FY2010 and FY2025 — management has been retiring shares, which concentrates each remaining owner's claim. Capital Discipline scores it 44/100.

Put together: Pricing Power is the strongest of the four filters (99/100) and Returns on Capital the weakest (0/100), which is how BRTX lands at 50/100 — a Shallow moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

RevenueSales, as filed$359700 FY2025

Gross marginRevenue kept after cost of goods93.4% FY2025

Return on invested capitalOperating profit on the capital employed−114.3% FY2024

Owner earningsCash an owner could take out−$14.1M FY2025

Gaps in a line mean that item isn’t in BRTX’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Moat Score history

Moat Score over timeLast scored reading of each day, on the 0–100 scale49.5 / 100

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — BRTX has read Shallow moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Track record

How BIORESTORATIVE THERAPIES, INC.’s moat rated in each of the years we can reconstruct from its filings — scored only on what was knowable at the time — and what its price and returns did afterward. The score never saw a price; the two are joined only in hindsight, for education, not as a signal.

As-of Moat Score (dot colored by tier)Indexed price (total-return (dividends reinvested))Rated Wide-moat that year

How to read this: each dot is what the engine would have scored BRTX on that December 31; the line below is its total-return price path (dividends reinvested) in the years since.

Two tracks, one timeline: the score has its own 0–100 scale (top), the price its own 100-based scale (bottom) — never a shared axis. The price path is a total-return (dividends reinvested) index built from the same data the forward returns use; gaps in the score line are years with no reconstructed rating (see the table for why). The Table view carries every value.

What followed, in the years it rated Wide

In the reconstructed history shown, BRTX did not rate Wide-moat in any year, so there is no wide-moat track record to report. That absence is itself the honest answer — we don’t manufacture a comparison where the rating never earned one.

Healthcare context

#125 of 461 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

#123COO The Cooper Companies, Inc.49.5 out of 100, Shallow moatShallow moat
#124STAA STAAR SURGICAL CO49.5 out of 100, Shallow moatShallow moat
#126IDXG INTERPACE BIOSCIENCES, INC.49.3 out of 100, Shallow moatShallow moat
#127BIO Bio-Rad Laboratories, Inc.49.0 out of 100, Shallow moatShallow moat

Compare BRTX with its nearest peers →All Healthcare companies on the Index →

Common questions about BRTX

Does BIORESTORATIVE THERAPIES, INC. have an economic moat?: Based on its FY2025 SEC filings, the Moat Index scores BIORESTORATIVE THERAPIES, INC. (BRTX) 49.5 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 99, returns on capital 0, balance-sheet safety 55, capital discipline 44.
How has BRTX's Moat Score changed over time?: The record logs 4 readings since Jul 17, 2026; the latest reads 49.5 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

Embed this score on your site

One iframe, no script. The badge shows BRTX’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/BRTX"
  width="340" height="150" style="border:0"
  title="BRTX Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell BRTX. See the disclaimer.